30 closest matches · ranked by relevance
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma
Primary: Objective Response Rate (ORR) — 2; 0 Participants
Ovarian Cancer
Primary: Progression-free Survival (PFS) — 13.7; 8.4 months
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Response Rate (RR) Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 3; 15; 5 Participants
Primary Peritoneal Carcinoma · Recurrent Ovarian Carcinoma · Stage IV Ovarian Cancer
Primary: Median Time to Progression — 7.2 months
Recurrent Ovarian Cancer · Recurrent Fallopian Tube Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 5.29; 5.55; 3.76 months — p=0.3293
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1 — 0; 1 participants
Recurrent Epithelial Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer
Primary: Overall Response Rate (ORR) — 4 participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ovarian Epithelial Tumor
Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate (ORR) — 109; 37 Count of Participants — p=0.002
Fallopian Tube Clear Cell Adenocarcinoma · Ovarian Clear Cell Adenocarcinoma · Recurrent Fallopian Tube Carcinoma
Primary: The Percentage of Patients Who Survive Progression Free for at Least 6 Months — 23 percentage of participants
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression Free Survival (PFS) Rate at 6 Months — 55.2 percentage of patients
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Objective Tumor Response — 12.2; 31.4 percentage of participants
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer · Stage IV Ovarian Epithelial Cancer
Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants
Ovarian Cancer
Primary: Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) — 8.4; 4.8 Months — p=<0.00001
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Tumor Response — 7; 30; 12; 6 participants
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Progression-free Survival (PFS) > 6 Months — 8.0 percentage of participants
Ovarian Cancer
Primary: Occurrence of a DLT (Dose Limiting Toxicity) — 0; 1 Participants
Ovarian Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival (PFS) — 56 percentage of participants
Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Response Rate to the Combination of Gemcitabine and Docetaxel in Patients With Platinum Sensitive and Resistant Epithelial Ovarian or Peritoneal Cancer. — 62 percentage…
Borderline Ovarian Serous Tumor · Micropapillary Serous Carcinoma · Ovarian Serous Adenocarcinoma
Primary: Progression-free Survival (PFS) — 7.2; 13.0 months
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Four Cycle Progression-free Survival Rate — 8 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Serologic Response (Change in CA125 Level) — 2 participants
Ovarian Carcinoma · Peritoneal Neoplasms
Primary: Tumor Response Type: CR, PR, SD or PD — 1; 4; 9; 6 Participants
Epithelial Ovarian Cancer
Primary: Efficacy: Progression-free Survival (PFS) — 4.3; 2.8; 5.3; 2.8 Months — p=0.0220
Ovarian Neoplasms · Fallopian Tube Neoplasms · Primary Peritoneal Neoplasms
Primary: 6 Month Progression Free Survival — 0 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Clinical Benefit Rate [CBR] — 12 Participants